Delivery Order SPE2DB22D3102-SPE2DB23FL2XM
- Not listed
- This federal contract award is for the delivery of CEFIXIME 400 MG CAPSULE UD 10S to the Defense Logistics Agency (DLA), a defense agency. The contract has a ceiling value of $1,210.50 and is a Firm Fixed Price Delivery Order. The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp also holds a significant Indefinite Delivery...
- This federal contract award from the Defense Logistics Agency (DLA) was issued to Amerisourcebergen Drug Corp, a division of Amerisourcebergen Corporation, a global pharmaceutical sourcing and distribution company. The $11,519.69 firm fixed price delivery order is for the supply of CEFIXIME 400 MG CAPSULE 50S, with a completion date of February 14, 2024. This award does not have a set-aside designation. Amerisourcebergen Drug Corp serves as a prime contractor providing a wide range of...
- This federal contract award is for the delivery of CEFIXIME 200MG/5ML 1S medical supplies to the Medical Supply Chain, a division of the Defense Logistics Agency (DLA). The contract, valued at $12,336.42, was awarded to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., a major pharmaceutical distribution company. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of June 20, 2023. The contract is not designated with a set-aside...
- This is a delivery order federal contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), an agency of the U.S. Department of Defense. The contract is for the delivery of CEFIXIME 400 MG CAPSULE 50S, a pharmaceutical product, with a ceiling value of $3,926.22 and a completion date of July 11, 2025. The contract is a Firm Fixed Price Delivery Order, without a set-aside designation, indicating open...
- This federal contract award from the Defense Logistics Agency (DLA) was made to Amerisourcebergen Drug Corp's Corporate Office division, a major pharmaceutical distributor. The $3,159.96 Firm Fixed Price Delivery Order provides Cefixime 400 mg capsules to the DLA. This award is part of Amerisourcebergen's larger $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a wide range of pharmaceutical...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,541.09, is for the delivery of 4,563,004,539 units of the anti-infective medication Cefixime 400 mg capsules. The contract has an ultimate completion date of December 6, 2023 and is a firm fixed-price delivery order. This award is not designated as a set-aside contract. AmerisourceBergen Drug...
- This federal contract award is a delivery order issued to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $2,598.24, is for the provision of CEFIXIME 400 MG CAPSULE 50S, a generic antibiotic medication. The award is not designated as a set-aside contract, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with...
- This federal contract award, valued at $5,276.85, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is for the delivery of 4560896490 - CEFIXIME 200 MG/5 ML SUSP 50ML, a pharmaceutical product. The contract has a completion date of May 11, 2023 and is a Firm Fixed Price Delivery Order. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,870.33, is for the delivery of CEFIXIME 400 MG CAPSULE 50S, a medication used to treat various bacterial infections. The contract has no set-aside designation, indicating it was an open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,456.32 to AmerisourceBergen Drug Corp for the supply of Cefixime 400 mg capsules (50-count units). This contract, issued on December 9, 2025, represents a firm fixed-price delivery order with an ultimate completion date of December 10, 2025. The award was made through open competition with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- SPE2DB22D3102Indefinite Delivery Contract
- SPE2DB22D3102-SPE2DB23FL2XMDelivery Order
This federal contract award is for the delivery of CEFIXIME 400 MG CAPSULE 50S to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., which is a major pharmaceutical distribution company. The contract is a Delivery Order with a Firm Fixed Price pricing type, with a ceiling value of $6,303.74 and an ultimate completion date of September 21, 2023. The contract is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00, which serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This includes specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits across multiple therapeutic domains. The company also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.3k | 9/20/23 |